Mass spectrometric detection in chromatography. Trends and perspectives

Cserháti, Tibor

doi:10.1002/bmc.165

Cited by 12 publications

(3 citation statements)

References 65 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some recently published review articles adequately address the salient requirements for development of assays to support and justify the continued development of NCEs during various stages of discovery and clinical phases of development (Srinivas, 2004a(Srinivas, ,b, 2005Kataoka, 2005;Zhou et al, 2005). These articles and many more available in the literature collectively address variety of method development and validation considerations for both chiral and achiral substrates which are quite applicable in the context of either chiral or achiral CYP2D6 substrates (Zhou et al, 2005;Srinivas, 2004aSrinivas, ,b, 2005Kataoka, 2005;Halket et al, 2004;Tiller et al, 2003;Williams and Wainer, 2002;Ackermann et al, 2002;Hoptgartner and Bourgogne, 2003;Cserhati, 2002;Timmermann et al, 2001;Jemal, 2001;Ayrton et al, 1998a,b;Frye et al, 1997).…”

Section: Analytical Perspectivesmentioning

confidence: 95%

Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implications

Srinivas

2006

Biomedical Chromatography

View full text Add to dashboard Cite

The concepts of drug development have evolved over the last few decades. Although number of novel chemical entitities belonging to varied classes have made it to the market, the process of drug development is challenging, intertwined as it is with complexities and uncertainities. The intention of this article is to provide a comprehensive review of novel chemical entities (NCEs) that are substrates to cytochrome P450 (CYP) 2D6 isozyme. Topics covered in this review aim: (1) to provide a framework of the importance of CYP2D6 isozyme in the biotransformation of NCEs as stand-alones and/or in conjunction with other CYP isozymes; (2) to provide several case studies of drug disposition of important drug substrates, (3) to cover key analytical perspectives and key assay considerations to assess the role and involvement of CYP2D6, and (4) to elaborate some important considerations from the development point of view. Additionally, wherever applicable, special emphasis is provided on chiral drug substrates in the various subsections of the review.

show abstract

Section: Analytical Perspectivesmentioning

confidence: 95%

Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implications

Srinivas

2006

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Since the analytical field as a whole has shown significant technological advancement not only in the field of separation science but also in the availability of sensitive instruments, reagents, accessories such as chromatographic columns, novel stationary phases, column switching options, automation tools, improvement in extraction procedures, novel derivatization reagents and enhancement in detection systems with MS interfaces permitting different ionization schemes and approaches to increase the throughput of analysis and availability of trained and skilled personnel, the task of developing sound bioanalytical assay(s) can be achieved very easily (Toyo'oka, 2005;Kataoka, 2005;Paull and Nesterenko, 2005;Halket et al, 2005;Trivedi et al, 2005;Locatelli et al, 2005;Taylor PJ, 2004;Veuthey et al, 2004;Herron et al, 2004;Bhushan and Bruckner, 2004;Claessens and van Straten, 2004;Marshall et al, 2004;Kostiaimen et al, 2003;Deng et al, 2003;Naidong, 2003;Tiller et al, 2003;Li et al, 2003;Hoptgartner and Bourgogne, 2003;Huikko et al, 2003;Srinivas and Mamidi, 2003;Schellen et al, 2003;Cserhati, 2002;Williams and Wainer, 2002;Toyo'oka, 2002;Lim and Lord, 2002;Morrand et al, 2001;Plumb et al, 2001;Sun et al, 2001;Meguro et al, 2001;Xia et al, 2000).…”

Section: Introductionmentioning

confidence: 98%

Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations

Srinivas

2006

Biomed. Chromatogr.

View full text Add to dashboard Cite

The development of sound bioanalytical method(s) is of paramount importance during the process of drug discovery and development culminating in a marketing approval. Although the bioanalytical procedure(s) originally developed during the discovery stage may not necessarily be fit to support the drug development scenario, they may be suitably modified and validated, as deemed necessary. Several reviews have appeared over the years describing analytical approaches including various techniques, detection systems, automation tools that are available for an effective separation, enhanced selectivity and sensitivity for quantitation of many analytes. The intention of this review is to cover various key areas where analytical method development becomes necessary during different stages of drug discovery research and development process. The key areas covered in this article with relevant case studies include: (a) simultaneous assay for parent compound and metabolites that are purported to display pharmacological activity; (b) bioanalytical procedures for determination of multiple drugs in combating a disease; (c) analytical measurement of chirality aspects in the pharmacokinetics, metabolism and biotransformation investigations; (d) drug monitoring for therapeutic benefits and/or occupational hazard; (e) analysis of drugs from complex and/or less frequently used matrices; (f) analytical determination during in vitro experiments (metabolism and permeability related) and in situ intestinal perfusion experiments; (g) determination of a major metabolite as a surrogate for the parent molecule; (h) analytical approaches for universal determination of CYP450 probe substrates and metabolites; (i) analytical applicability to prodrug evaluations-simultaneous determination of prodrug, parent and metabolites; (j) quantitative determination of parent compound and/or phase II metabolite(s) via direct or indirect approaches; (k) applicability in analysis of multiple compounds in select disease areas and/or in clinically important drug-drug interaction studies. A tabular representation of select examples of analysis is provided covering areas of separation conditions, validation aspects and applicable conclusion. A limited discussion is provided on relevant aspects of the need for developing bioanalytical procedures for speedy drug discovery and development. Additionally, some key elements such as internal standard selection, likely issues of mass detection, matrix effect, chiral aspects etc. are provided for consideration during method development.

show abstract

“…However, TLC can be coupled with spectrometric methods such as IR, Raman, and mass spectrometry for compound specific information. Imaging detection using information rich techniques is a burgeoning area of research in planar chromatography. − In some instances, including the work described herein, separated spots are moved from the TLC plate to a detection-compatible planar medium using a blotting process. In particular, blotting has been used effectively with mass spectrometry and gas chromatography/mass spectrometry. − …”

mentioning

confidence: 99%

Surface Enhanced Raman Scattering Imaging of Developed Thin-Layer Chromatography Plates

2013

View full text Add to dashboard Cite

A method for hyphenating surface enhanced Raman scattering (SERS) and thin-layer chromatography (TLC) is presented that employs silver-polymer nanocomposites as an interface. Through the process of conformal blotting, analytes are transferred from TLC plates to nanocomposite films before being imaged via SERS. A procedure leading to maximum blotting efficiency was established by investigating various parameters such as time, pressure, and type and amount of blotting solvent. Additionally, limits of detection were established for test analytes malachite green isothiocyanate, 4-aminothiophenol, and Rhodamine 6G (Rh6G) ranging from 10(-7) to 10(-6) M. Band broadening due to blotting was minimal (∼10%) as examined by comparing the spatial extent of TLC-spotted Rh6G via fluorescence and then the SERS-based spot size on the nanocomposite after the blotting process. Finally, a separation of the test analytes was carried out on a TLC plate followed by blotting and the acquisition of distance × wavenumber × intensity three-dimensional TLC-SERS plots.

show abstract

Mass spectrometric detection in chromatography. Trends and perspectives

Cited by 12 publications

References 65 publications

Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implications

Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implications

Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations

Surface Enhanced Raman Scattering Imaging of Developed Thin-Layer Chromatography Plates

Contact Info

Product

Resources

About